Published March 12, 2021 | Version v1
Dataset Open

Integrative methylome-transcriptome analysis unravels cancer-cell vulnerabilities in infant MLL-rearranged B-ALL (Datasets and additional tables))

  • 1. Fundación para la Investigación Biosanitaria de Asturias (FINBA), Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Instituto Universitario de Oncología del Principado de Asturias (IUOPA), Hospital Universitario Central de Asturias (HUCA), Universidad de Oviedo, Principado de Asturias, Spain. Nanomaterials and Nanotechnology Research Center (CINN-CSIC), Universidad de Oviedo, Principado de Asturias, Spain
  • 2. Josep Carreras Leukemia Research Institute-Campus Clinic, Department of Biomedicine, School of Medicine, University of Barcelona, Barcelona, Spain. Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), ISCIII, Barcelona, Spain
  • 3. Josep Carreras Leukemia Research Institute-Campus Clinic, Department of Biomedicine, School of Medicine, University of Barcelona, Barcelona, Spain. Instituto de Biomedicina y Biotecnología de Cantabria (IBBTEC), Universidad de Cantabria-CSIC, Santander, Spain
  • 4. Fundación para la Investigación Biosanitaria de Asturias (FINBA), Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Instituto Universitario de Oncología de Asturias (IUOPA), Hospital Universitario Central de Asturias (HUCA), Universidad de Oviedo, Asturias, Spain. Josep Carreras Leukemia Research Institute-Campus Clinic, Department of Biomedicine, School of Medicine, University of Barcelona, Barcelona, Spain
  • 5. Josep Carreras Leukemia Research Institute-Campus Clinic, Department of Biomedicine, School of Medicine, University of Barcelona, Barcelona, Spain. Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), ISCIII, Barcelona, Spain. Molecular Cytogenetics Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain
  • 6. Fundación para la Investigación Biosanitaria de Asturias (FINBA), Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Instituto Universitario de Oncología de Asturias (IUOPA), Hospital Universitario Central de Asturias (HUCA), Universidad de Oviedo, Asturias, Spain
  • 7. Hematology Diagnostic Laboratory. Hospital Universitario Niño Jesús, Madrid. Spain
  • 8. Centro Ricerca Tettamanti, Department of Paediatrics, University of Milano Bicocca, Fondazione MBBM, Monza, Italy
  • 9. Pediatric Hematology. Armand Trousseau Hospital. Paris. France
  • 10. Princess Maxima Center for Paediatric Oncology, Utrecht, The Netherlands
  • 11. Instituto de Biomedicina y Biotecnología de Cantabria (IBBTEC), Universidad de Cantabria-CSIC, Santander, Spain
  • 12. Fundación para la Investigación Biosanitaria de Asturias (FINBA), Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Instituto Universitario de Oncología del Principado de Asturias (IUOPA), Hospital Universitario Central de Asturias (HUCA), Universidad de Oviedo, Principado de Asturias, Spain
  • 13. Josep Carreras Leukemia Research Institute-Campus Clinic, Department of Biomedicine, School of Medicine, University of Barcelona, Barcelona, Spain. Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), ISCIII, Barcelona, Spain. Instituciò Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain

Description

B-cell acute lymphoblastic leukemia (B-ALL) is the most common childhood cancer. As predicated by its prenatal origin, infant B-ALL (iB-ALL) shows an exceptionally silent DNA mutational landscape, suggesting that alternative epigenetic mechanisms may significantly contribute to its leukemogenesis. We have extensively characterized the DNA methylome and the transcriptome lansdcape of 40 patients with de novo MLL rearranged (MLLr) and non-MLLr iB-ALL leukemias uniformly treated according to Interfant-99/06 protocol. iB-ALL methylome signatures display a plethora of common and specific alterations associated with chromatin states related to enhancer and transcriptional control. Further methylome-transcriptome integration identified consistent cancer-cell vulnerabilities, revealed a robust iB-ALL-specific gene expression-correlating dmCpG signature and confirmed an epigenetic control of AP-1 and RUNX members in reshaping the molecular network of MLLr iB-ALL. Pharmacological inhibition or functional ablation of AP-1 activity resulted in dramatic in vitro and in vivo leukemia proliferation defects, providing rationale for new potential therapeutic avenues in iB-ALL. This dataset contains information related to dataframes, databases, scripts and supplementary material mentioned in the original manuscript.

Files

Data.zip

Files (6.8 GB)

Name Size Download all
md5:67931b682e422a2792214dc3d27d4813
1.9 GB Preview Download
md5:98024ceb3b111144e572063320841207
4.3 GB Preview Download
md5:5d6bf9470ce33ae183228dbc044d3ff5
12.7 kB Preview Download
md5:1773cf508dfc93c771b3fbd15cc4b381
111.3 kB Preview Download
md5:a2fc2d172b6f6c13667c7caa6f036e63
5.8 kB Download
md5:5492d80fb7c883b1bd2d14aefef016a2
126.1 kB Download
md5:cca72863c2f14501430b7574f0cf041d
963.4 kB Download
md5:d31b0f34fded2c75a2a9cd184966ee15
1.1 MB Download
md5:4c1c5e49042f6694e76b9597c2484e69
1.6 MB Download
md5:76e24e9ca1dcdb2abe1404ecabdf044e
41.2 kB Download
md5:96c001302b35271c4278a8ebb6cd6534
103.4 kB Download
md5:0671186c8abca11871f11fdbaf1d054b
1.8 MB Download
md5:05d2b41f2bc01e25d2168d0bde310b3a
64.3 kB Download
md5:13a56a7090f82b3d19d78b2b9bdadcb0
1.4 MB Download
md5:cfe9837b0dc86f1b01a14117b57dc501
174.1 kB Download
md5:eb2ed7cea7fbd9534946b2606ca5da55
21.3 MB Download
md5:0b96bafd69e164ded351a4df97fb2020
7.8 kB Download
md5:72049f8c4f5a6ecb62d362478e429350
17.8 kB Download
md5:a106a2cd4c20e9264e6dec3825b5b531
15.3 kB Download
md5:d1fc731c796e766361bacfd8e2e22b40
209.3 kB Download
md5:d54480010b9f6d78fac16924b578432d
23.6 MB Download
md5:e4e7a4104c325ac1194d806ff4fcaaa8
203.0 kB Download
md5:a4983e4423832c523ba6b38900fc489d
819.8 kB Download
md5:b26402cfeeff2b48629b90ee75e327c2
49.5 kB Download
md5:3d8bb74455816ffda016a8a2a9557320
573.5 MB Preview Download

Additional details

Funding

INFANTLEUKEMIA – GENOMIC, CELLULAR AND DEVELOPMENTAL RECONSTRUCTION OF INFANT MLL-AF4+ ACUTE LYMPHOBLASTIC LEUKEMIA 646903
European Commission
IT4B-ALL – Therapeutic immunotherapy targeting NG2 and CD22 antigens for MLL-rearranged and MLL-germline B-cell Acute Lymphoblastic Leukemia 811220
European Commission